Shorla Pharma’s SH-111 treatment is being designed as an alternative therapy for T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). It will be targeted at paediatric patients over the age of one whose disease has not responded or has relapsed following at least two chemotherapy sessions.
T-cell leukaemia is a fast-progressing type of blood and bone marrow cancer which affects the lymphoid-cell-producing stem cells. It is the most common type of leukaemia that affects children, with around 85% of cases occurring in those younger than 15 years of age.
